Seminars in arthritis and rheumatism最新文献

{"title":"Real-world comparative effectiveness study of Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis","authors":"Soo-Kyung Cho ,&nbsp;Se Rim Choi ,&nbsp;Hye Won Kim ,&nbsp;Eunwoo Nam ,&nbsp;Sang Won Lee ,&nbsp;Shin-Seok Lee ,&nbsp;Hye-Soon Lee ,&nbsp;Sung-Hoon Park ,&nbsp;Yeon-Ah Lee ,&nbsp;Sung Hae Chang ,&nbsp;Min-Chan Park ,&nbsp;Hyoun-Ah Kim ,&nbsp;Seung-Ki Kwok ,&nbsp;Hyun-Sook Kim ,&nbsp;Bo Young Yoon ,&nbsp;Yong-Gil Kim ,&nbsp;Hae-Rim Kim ,&nbsp;Jae Hoon Kim ,&nbsp;Jisoo Lee ,&nbsp;Jeongim Choi ,&nbsp;Yoon-Kyoung Sung","doi":"10.1016/j.semarthrit.2025.152720","DOIUrl":"10.1016/j.semarthrit.2025.152720","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the real-world effectiveness and safety of Janus kinase inhibitors (JAKis) compared to biologic disease-modifying antirheumatic drugs (bDMARDs) in Korean patients with rheumatoid arthritis (RA) who have not previously been treated with either JAKis or bDMARDs.</div></div><div><h3>Methods</h3><div>This prospective, multicenter, observational study was conducted at 17 centres in the Republic of Korea. Patients with an inadequate response to methotrexate were enrolled and started treatment with either JAKis or bDMARDs. The primary endpoint was the proportion of patients achieving low disease activity (LDA) at 24 weeks, measured by the disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR). Secondary endpoints included the remission rate at 24 weeks, and LDA and remission rates at 48 weeks. Safety was assessed by the exposure-adjusted event rate (EAER) of adverse events (AEs), adjusted for length of the follow-up period and presented per 100 person-years.</div></div><div><h3>Results</h3><div>A total of 506 patients were enrolled, with 253 patients in each group. Among bDMARD users, 60.1 % received tumour necrosis factor inhibitors (TNFis; <em>n</em> = 152) and 39.9 % received non-TNFis (<em>n</em> = 101). At 24 weeks, 48.2 % of the JAKi group achieved LDA, as did 42.7 % of the bDMARD group. Remission rates at 24 weeks were 28.9 % for the JAKi group and 27.3 % for the bDMARD group. At 48 weeks, there were no significant intergroup differences in the EAER of overall AEs.</div></div><div><h3>Conclusions</h3><div>In this observational real-world study of Korean patients with RA who were eligible for targeted therapy, JAKis demonstrated comparable effectiveness and safety to bDMARDs.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152720"},"PeriodicalIF":4.6,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the time to the onset of lupus nephritis impact renal disease presentation and outcomes?","authors":"Fadi Kharouf,&nbsp;Pankti Mehta,&nbsp;Qixuan Li,&nbsp;Dafna D Gladman,&nbsp;Zahi Touma,&nbsp;Laura P Whittall Garcia","doi":"10.1016/j.semarthrit.2025.152724","DOIUrl":"10.1016/j.semarthrit.2025.152724","url":null,"abstract":"<div><h3>Objectives</h3><div>Lupus nephritis (LN) most commonly develops in the initial years after Systemic Lupus Erythematosus (SLE) onset. We aimed to investigate the impact of the time to LN onset on the clinical presentation and outcomes of LN.</div></div><div><h3>Methods</h3><div>We included 246 inception cohort patients who developed LN during follow-up. We categorized patients into three groups based on the time to LN onset: group 1 (early, ≤1 year, 160 patients), group 2 (intermediate, &gt;1 to ≤5 years, 42 patients), and group 3 (delayed, &gt;5 years, 44 patients). The outcomes assessed were complete proteinuria recovery (CPR) at one year, the occurrence of an adverse composite outcome (end-stage kidney disease [ESKD], a sustained ≥40 % decline in eGFR, or death), and the development of subsequent LN flares. Cox proportional hazard models were used to study associations with the outcomes.</div></div><div><h3>Results</h3><div>At baseline, the median [IQR] age was 34.3 [26.2, 44.7] years, with a median disease duration of 0.6 [0.2, 2.6] years. Delayed LN patients were older at baseline, had higher SDI, used glucocorticoids and immunosuppressives less frequently, and were less likely to achieve CPR at 1 year. Early LN patients had the lowest risk of developing the adverse composite outcome. In the Cox models, compared to early LN, intermediate LN was associated with an increased risk of developing the adverse composite outcome and showed a trend towards a higher association with subsequent LN flares.</div></div><div><h3>Conclusions</h3><div>Intermediate LN, occurring between the first and fifth year after SLE onset, is associated with the worst renal outcomes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152724"},"PeriodicalIF":4.6,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis-associated interstitial lung disease in countries across the world","authors":"Sascha L Heckert ,&nbsp;Tjardo D Maarseveen ,&nbsp;Emiel R Marges ,&nbsp;Arvind Chopra ,&nbsp;David Vega-Morales ,&nbsp;Riette du Toit ,&nbsp;Lai Ling Winchow ,&nbsp;Nimmisha Govind ,&nbsp;Carlos E Toro-Gutiérrez ,&nbsp;Rachel Knevel ,&nbsp;Annette HM van der Helm–van Mil ,&nbsp;Tom WJ Huizinga ,&nbsp;Cornelia F Allaart ,&nbsp;Sytske Anne Bergstra","doi":"10.1016/j.semarthrit.2025.152719","DOIUrl":"10.1016/j.semarthrit.2025.152719","url":null,"abstract":"<div><h3>Objectives</h3><div>We aimed to describe the incidence of RA-ILD in various countries worldwide, and to explore its association with RA disease activity.</div></div><div><h3>Methods</h3><div>In 5 countries, data on RA-ILD (clinical diagnosis based on chest X-ray or CT) were collected RA patients of two observational databases (METEOR, EAC). We investigated a possible association between disease activity over time and RA-ILD.</div></div><div><h3>Results</h3><div>16,663 patients with RA with variable disease duration were evaluated. At the first visit recorded in the database, 1/1077 (0.09 %) patients from The Netherlands, 63/11,787 (0.53 %) from India, 8/629 (1.27 %) from South Africa, 6/424 (1.42 %) from Mexico and 17/2728 (0.62 %) from Colombia had an RA-ILD diagnosis. The incidence rate of RA-ILD in patients with newly diagnosed RA was 3.8 (95 % CI 1.6 to 9.1) per 1000 patient years in The Netherlands, 1.6 (95 % CI 1.0 to 2.5) in India and 6.6 (95 % CI 2.5–17.5) in South Africa. The OR for RA-ILD development, per point increase in DAS28 over time was 1.19 (95 % CI 0.34 to 4.22). Disease activity after the RA-ILD diagnosis or a matched timepoint was statistically significantly higher in patients with RA-ILD than in controls (β 0.56 (95 % CI 0.18 to 0.93). There were no clear differences in DMARD use between the two groups.</div></div><div><h3>Conclusion</h3><div>Despite slight differences in RA-ILD prevalence and incidence between countries, the incidence of RA-ILD in daily practice is low in our RA population from different continents. Patients with RA-ILD had a higher disease activity than patients without RA-ILD, and were more often ACPA positive and/or (former) smokers.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152719"},"PeriodicalIF":4.6,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical prediction models for medication adverse events in patients with rheumatic and musculoskeletal conditions: A systematic literature review","authors":"Christina Diomatari ,&nbsp;Glen P Martin ,&nbsp;David A. Jenkins ,&nbsp;Meghna Jani","doi":"10.1016/j.semarthrit.2025.152728","DOIUrl":"10.1016/j.semarthrit.2025.152728","url":null,"abstract":"<div><h3>Objectives</h3><div>This systematic review aims to identify, summarize, and evaluate the methodological quality of existing clinical prediction models (CPMs) that predict adverse events (AEs) associated with medications prescribed for rheumatic and musculoskeletal diseases (RMDs).</div></div><div><h3>Methods</h3><div>We searched PubMed, Embase, and Medline databases up to March 2024. Studies were included if they developed multivariable CPM predicting AEs in adult patients using RMD medications. Data extraction and quality assessment were conducted using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) and Prediction model Risk Of Bias Assessment Tool (PROBAST) checklists to ensure consistent reporting and assess the risk of bias (ROB).</div></div><div><h3>Results</h3><div>Of 2406 studies identified, 1734 titles/abstracts were screened, and 38 were reviewed in full. Twelve studies reporting 17 CPMs met eligibility criteria. Most CPMs (76.4 %) focused on rheumatoid arthritis and disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate (69.2 %) and biologic drugs (15.3 %). Cox proportional hazards or logistic regression models were commonly used. Twelve models (70.5 %) had high overall ROB due to inappropriate variable selection methods and sample size.</div></div><div><h3>Conclusions</h3><div>This is the first systematic review summarising CPMs for AEs associated with RMD medications. It highlights that existing CPMs are affected by methodological pitfalls, including inappropriate variable selection and lack of clear sample size justification. Future models could consider a broader range of RMDs and medications. Emerging methods such as machine learning with the ability to model complex interactions, and multi-outcome CPMs to predict several AEs to one class of drug may improve predictions.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152728"},"PeriodicalIF":4.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep disorders in rheumatoid arthritis: Incidence, risk factors and association with dementia","authors":"Roslin Jose George ,&nbsp;Rakesh Kumar ,&nbsp;Sara J Achenbach ,&nbsp;Edward Lovering ,&nbsp;Ryan J Lennon ,&nbsp;John M Davis III ,&nbsp;Diego Z. Carvalho ,&nbsp;Cynthia S Crowson ,&nbsp;Elena Myasoedova","doi":"10.1016/j.semarthrit.2025.152722","DOIUrl":"10.1016/j.semarthrit.2025.152722","url":null,"abstract":"<div><h3>Background/Objective</h3><div>We aimed to examine the incidence of sleep disorders (SD) in individuals with rheumatoid arthritis (RA) vs. non-RA comparators, evaluate risk factors for SD, and assess the association between incident SD and dementia in RA.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included residents aged ≥50 years within an 8-county region of Minnesota who first met the 1987 ACR criteria for RA in 1980–2014. Individuals with RA were matched 1:1 with non-RA individuals on age, sex, and calendar year of RA incidence. Data on SD, cardiovascular disease (CVD) risk factors, CVD and other comorbidities were collected from the medical records.</div></div><div><h3>Results</h3><div>Nine hundred thirteen individuals with RA and 913 non-RA comparators were included (mean age: 65 years, 65 % female in both cohorts). During the median follow-up of 10.4 years in RA and 11.0 years in non-RA cohort, SD developed in 234 and 206 individuals, respectively. RA patients experienced an increased risk for any incident SD (HR 1.34; 95 % CI:1.11–1.61) and insomnia (HR 1.34; 95 % CI:1.03–1.73). Obesity, dyslipidemia, presence of CVD, depression, anxiety, and more recent calendar year of RA incidence were associated with increased risk of any SD in RA. There were no significant association between SD overall and by subtype with dementia in RA.</div></div><div><h3>Conclusion</h3><div>Individuals with RA (vs non-RA) experienced a significantly increased risk for any SD, particularly insomnia. CVD and CVD risk factors, as well as depression and anxiety increased the risk for incident SD in RA. There was no significant association between SD and dementia in RA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152722"},"PeriodicalIF":4.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis and the risk of 90-day readmission after hospitalization for heart failure","authors":"Sumanth R. Chandrupatla ,&nbsp;Jasvinder A. Singh","doi":"10.1016/j.semarthrit.2025.152727","DOIUrl":"10.1016/j.semarthrit.2025.152727","url":null,"abstract":"<div><h3>Aims</h3><div>To determine the association of rheumatoid arthritis (RA) diagnosis on the risk of 90-day readmissions and in-hospital mortality during readmission episode within 90 days after index heart failure (HF) hospitalization.</div></div><div><h3>Methods</h3><div>We used the 2016–2019 U.S. Nationwide Readmissions Database (NRD) to examine the association between RA diagnosis and 90-day readmission and in-hospital mortality risk during the 90-day readmission after index HF hospitalization. We performed multivariable-adjusted logistic regression, adjusting for patient demographics, Deyo-Charlson comorbidity index, median household income for patient's ZIP code, primary expected payer, patient state residency status, teaching status of hospital, hospital control, and hospital bed size. We calculated adjusted odds ratios (aOR) and 95 % confidence intervals (95 % CI).</div></div><div><h3>Results</h3><div>Of the 3,718,425 with index HF hospitalizations during 2016–2019, 32.7 % (<em>n</em> = 1,214,185) were readmitted within 90-days of the index heart failure hospitalization. We found that RA diagnosis was significantly associated with both 90-day readmission and in-hospital mortality during readmission within 90 days after index HF hospitalization, with aOR 1.16 (95 % CI, 1.13–1.19), and aOR 1.12 (95 % CI, 1.04–1.20), respectively in multivariable-adjusted analysis. These findings were confirmed in additional sensitivity analysis.</div></div><div><h3>Conclusion</h3><div>We demonstrated a significant association of RA with both 90-day readmission and in-hospital mortality in HF rehospitalizations. Targeted interventions and other treatment options need to be explored to reduce the additional risk of readmission and mortality for patients with RA and HF.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152727"},"PeriodicalIF":4.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical coronary artery calcification in systemic sclerosis using high-resolution chest CT: Identification, extent, and disease-specific risk factors","authors":"Esben U. Næser ,&nbsp;Frederik C. Enevoldsen ,&nbsp;Simon Winther ,&nbsp;Morten Bøttcher ,&nbsp;Klaus Søndergaard ,&nbsp;Ellen-Margrethe Hauge","doi":"10.1016/j.semarthrit.2025.152723","DOIUrl":"10.1016/j.semarthrit.2025.152723","url":null,"abstract":"<div><h3>Objectives</h3><div>Early detection of subclinical atherosclerosis is pivotal for preventing symptomatic coronary artery disease. This study aimed to compare the proportion of patients with systemic sclerosis (SSc) having an Agatston coronary artery calcification (CAC) score ≥100 using high-resolution computed tomography (HRCT) chest scans to a background population using cardiac CT scans, and to identify disease-specific risk factors for subclinical CAC in patients with SSc.</div></div><div><h3>Methods</h3><div>Logistic regression models, adjusted for cardiovascular risk factors, evaluated the odds ratio of patients having a CAC score ≥100. CAC scores for the background population were derived from two cardiac CT screening cohorts. CAC scores by HRCT chest scans were calibrated using a conversion factor to adjust for overestimation in comparison to CAC scores obtained from dedicated cardiac CT scans.</div></div><div><h3>Results</h3><div>HRCT chest scans from 394 patients with SSc were evaluated. In total, 116 (29.4 %) had a CAC score of 0, while 162 (41.1 %) had a CAC score ≥100. Disease duration (OR=1.05, 95 % CI 1.01–1.09) and a history of digital ulcers (OR=2.25, 95 % CI 1.31; 3.86) were independently associated with a CAC score ≥100. Compared to the background population, a significantly higher proportion of SSc patients had a CAC score ≥100 (35.0 % vs. 23.2 %, p&lt;0.001).</div></div><div><h3>Conclusion</h3><div>The identification of subclinical atherosclerosis using routine HRCT chest scans in patients with SSc offers the potential to detect individuals at increased risk of developing CAD and guide preventive treatment strategies. Additionally, digital ulcers appear to be a novel risk factor for subclinical CAD in these patients.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152723"},"PeriodicalIF":4.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: chest CT patterns and correlation with survival","authors":"Marta Casal Moura ,&nbsp;Yasmeen K. Tandon ,&nbsp;Thomas E. Hartman ,&nbsp;Jay H. Ryu ,&nbsp;Misbah Baqir","doi":"10.1016/j.semarthrit.2025.152726","DOIUrl":"10.1016/j.semarthrit.2025.152726","url":null,"abstract":"<div><h3>Background</h3><div>Interstitial lung disease (ILD) is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with usual interstitial pneumonia (UIP) being the most frequent pattern. The impact of different ILD patterns on clinical outcomes remains unclear.</div></div><div><h3>Methods</h3><div>Retrospective cohort study included patients with AAV (MPA and GPA) and ILD confirmed by chest CT scans between 1997 and 2021. ILD patterns were classified according to 2018 Fleischner Society criteria.</div></div><div><h3>Results</h3><div>Of 1862 patients in the Mayo AAV Cohort, 143 (7.7 %) had ILD on chest CT. The median age at the time of ILD diagnosis (occurring before AAV diagnosis in 26.6 %) was 69 years (IQR 61–75); 60 % were male, and 75 % were MPO-positive. On chest CT, “typical UIP” pattern was identified in 44 patients (30.8 %), whereas 13 (9.1 %) manifested “probable UIP” pattern, 37 (25.9 %) “indeterminate for UIP” pattern, and 49 (34.3 %) “non-UIP” pattern. Among MPO-ANCA patients, typical UIP pattern was most common (37.4 %), while non-UIP pattern was most common (58.3 %) among PR3-ANCA patients. Patients with typical UIP pattern, when compared to those with non-UIP pattern, were more commonly male (70.5 %), MPO-ANCA (90.0 %), diagnosed before the onset of AAV (40.9 %), and had reduced diffusion capacity on pulmonary function tests. The presence of typical UIP was related with higher survival at 12 months and 10 years in MPO-ANCA patients when compared to other ILD patterns (IRR 8.201 and IRR 2.179).</div></div><div><h3>Conclusions</h3><div>The typical UIP pattern in AAV-ILD is associated with better survival, particularly in MPO-ANCA patients, suggesting distinct mechanisms for ILD development in MPO vs. PR3-AAV.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152726"},"PeriodicalIF":4.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of the intima-media thickness by ultrasound for the diagnosis of giant cell arteritis: a systematic review","authors":"Camila Pitasi ,&nbsp;Fernando Lamarca ,&nbsp;Veronica Vilela ,&nbsp;Ana Beatriz Vargas-Santos ,&nbsp;Markus Aschwanden ,&nbsp;Stephan Imfeld ,&nbsp;Daniel Staub ,&nbsp;Thomas Daikeler","doi":"10.1016/j.semarthrit.2025.152725","DOIUrl":"10.1016/j.semarthrit.2025.152725","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the performance of quantitative intima-media thickness (IMT) measurement by ultrasound (US) for diagnosing GCA.</div></div><div><h3>Methods</h3><div>A systematic literature review of the following electronic databases was performed: PubMed, Embase, Web of Science, Scopus, Lilacs, and Google Scholar (no date and language restriction, last search June 3, 2024). Studies that tested IMT`s diagnostic accuracy as a primary outcome in GCA suspected patients were included. The quality of the studies was assessed using the QUADAS-2 tool.</div></div><div><h3>Results</h3><div>Among 2786 records screened by title and abstracts, 7 fulfilled the inclusion criteria. The proposed IMT cut-off values for vasculitis in between the studies varied between 0.4 and 0.44, and 0.81 and 1.2 mm for the temporal (TA) and the axillary artery (Axa), respectively. Most cut-off values were post hoc calculated. Diagnostic accuracy vis-à-vis qualitative judgement of the respective segments by US or MRI was high (sensitivities: 76 to 100 %, specificities: 85.7 to 100 %) despite the different cut-offs used. All studies have a high risk of bias in at least two QUADAS-2 domains due to patient selection issues, lack of US blinding, and use of the index test as part of the reference standard.</div></div><div><h3>Conclusion</h3><div>The seven studies had considerable drawbacks due to biases across several domains. This might explain the high reported diagnostic accuracy for defining vasculitis of the TA and Axa segments, despite different cut-off values and reference standards being used in these studies. Reliable IMT cut-off values of the TA and the Axa for diagnosing GCA are not yet available.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152725"},"PeriodicalIF":4.6,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of health-related quality of life in adults living with rheumatoid arthritis: a systematic review","authors":"Nejat Hassen ,&nbsp;Kasra Moolooghy ,&nbsp;Jacek Kopec ,&nbsp;Hui Xie ,&nbsp;Karim M Khan ,&nbsp;Diane Lacaille","doi":"10.1016/j.semarthrit.2025.152717","DOIUrl":"10.1016/j.semarthrit.2025.152717","url":null,"abstract":"<div><h3>Objective</h3><div>To systematically review contemporary studies identifying health-related quality of life (HRQoL) determinants in rheumatoid arthritis (RA) and synthesize the evidence.</div></div><div><h3>Methods</h3><div>Three electronic databases were searched for cross-sectional or prospective cohort studies published 2000 or later that identified HRQoL determinants using multivariable prediction models and evaluated HRQoL using the SF-36/12/8/6D or EQ-5D. Two authors conducted screening, data extraction, and quality assessment. Findings were synthesized using a narrative synthesis approach.</div></div><div><h3>Results</h3><div>Twenty-one studies were included. Seventy determinants were evaluated. Determinants were classified into five domains: (i) sociodemographic, (ii) RA-related, (iii) comorbidities and general health, (iv) health behaviours, and (v) psychosocial. RA-related determinants were the most studied determinants. Forty-four determinants were identified as statistically significant HRQoL determinants. Age and gender were the most evaluated determinants in the sociodemographic domain, but associations between older age and female gender and better HRQoL were inconsistent. Disease duration, disease activity, and physical function were the most evaluated determinants in the RA-related domain. Higher disease activity and worse physical function were associated with lower HRQoL, but association between longer disease duration and HRQoL was inconsistent. All comorbidities identified were associated with lower HRQoL. Exercise and sleep were the only significant determinants in the health behaviours domain and were associated with better HRQoL. Anxiety and depression were the most evaluated psychosocial variables and were associated with lower HRQoL.</div></div><div><h3>Conclusion</h3><div>HRQoL determinants were identified from multiple domains. The existing literature consists mostly of cross-sectional studies. More prospective studies are needed to assess temporal relationship between determinants and HRQoL.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152717"},"PeriodicalIF":4.6,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}